1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Funding Opportunity Number: HT942526TSCRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $3.5M total program funding.
Get alerted about grants like this
Get emailed when new opportunities from “Defense Health Agency Contracting Activity - DHACA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $3.5M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Tuberous Sclerosis Complex, Clinical Translational Research Award are due August 6, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Tuberous Sclerosis Complex, Clinical Translational Research Award is offered by Defense Health Agency Contracting Activity - DHACA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Idea Development Award (IDA) supports conceptually innovative and high-impact research that could ultimately lead to critical discoveries in tuberous sclerosis complex (TSC) research and/or improvements in patient care.Distinctive Features: This funding mechanism allows for established and new-to-the-field investigators. New-to-the-field investigators are independent investigators that are early in their faculty appointments and/or established investigators transitioned from other research fields into TSC research. Applications to the New-to-the-Field option will compete separately from the Established Investigators submitting to the regular Idea Development Award (IDA). Funding Opportunity Number: HT942526TSCRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $3.2M total program funding.
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. Funding Opportunity Number: HT942526TSCRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $3.5M total program funding.
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field.Distinctive Features: Preliminary Data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. Funding Opportunity Number: HT942526TSCRPEHDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.1M total program funding.
CMS awarded all 50 states their first-year slice of the $50 billion Rural Health Transformation Program in December 2025 — from $147M in New Jersey to $281M in Texas. Now the money is moving downstream: New Jersey and New York have already launched subaward RFAs, and rural hospitals, clinics, community organizations, and tribal groups are the eligible applicants. Here is how the allocation formula worked, what the money can and cannot fund, and the strategy to win a state subaward.
Read articleTitle III of the Defense Production Act lets the Pentagon hand non-dilutive capital to companies that expand domestic production of defense-critical materials and manufacturing — through a white-paper-first pathway run by the Air Force Research Laboratory (FA8650-19-S-5010) rather than a conventional grant competition. But the core DPA authorities sunset September 30, 2026 absent reauthorization, and the standing white-paper window has moved in and out of suspension. Here is how the Title III mechanism actually works, why it rewards companies that lead with a supply-chain vulnerability, and how to position before the authority cliff.
Read articleThe FY2026 Rural Health Network Advancement Program (HRSA-26-082) offers six awards of roughly $500,000 to help independent rural hospitals and clinics form integrated networks without surrendering local ownership. With a July 24, 2026 deadline and a pilot design that rewards genuine collaboration over merger, here is who qualifies, what a fundable network looks like, and how small rural providers should approach it.
Read article